FY23 revenue consensus $327.19M. The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million. While flat year-over-year, we expect reductions in R&D spending in 2023 following the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the BCX10013 clinical program, offset by increases in SG&A to support the U.S. launch and global expansion of ORLADEYO.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
- BioCryst presents new data from APeX-S clinical trial evaluating ORDALEYO
- BioCryst price target lowered to $10 from $13 at Evercore ISI
- BioCryst to Report First Quarter 2023 Financial Results on May 3
- BioCryst announces $450M financing commitment from Pharmakon